Jaap W. Groothoff - Publications

Clinical Benefits Associated With Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia.

Journal: Journal of the American Heart Association

Published: August 20, 2026

Primary hyperoxaluria type 1-current practice in the siRNA era: an ERA Genes & Kidney Working Group survey.

Journal: Clinical kidney journal

Published: December 05, 2025

Natural History of Advanced Primary Hyperoxaluria Type 1: A Retrospective Study.

Journal: Kidney medicine

Published: November 10, 2025

Resting-state EEG reveals slowing and altered functional connectivity in children and young adults with severe chronic kidney disease.

Journal: Clinical neurophysiology practice

Published: September 27, 2025

APOL1 kidney risk variants and outcomes in children with congenital anomalies of the kidney and urinary tract.

Journal: Pediatric nephrology (Berlin, Germany)

Published: September 04, 2025

Transition of patients with hereditary nephropathies from paediatric to adult care.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: June 18, 2025

Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: May 14, 2025

New opportunities for accessing promising non-oncological orphan drugs.

Journal: The Lancet regional health. Europe

Published: January 25, 2025

Controlled access to lumasiran in primary hyperoxaluria type 1: evaluation of a new access route for orphan drugs in the Netherlands.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: January 09, 2025

PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients With Primary Hyperoxaluria Type 1.

Journal: Kidney international reports

Published: December 20, 2024

Global access to management of primary hyperoxaluria: a survey on behalf of OxalEurope, G&K Working Group of the ERA and ESPN.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: September 16, 2024

Long-term lumasiran therapy final results from a Phase 2 open-label extension study in primary hyperoxaluria.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: August 08, 2024